New Growth Models In China: McKinsey-PharmAsia Summit Report Preview
This article was originally published in The Pink Sheet Daily
With increased pricing pressure on branded generics, MNCs in China need to fundamentally redesign their business models with stronger market-access capabilities and to shift resources away from brands under acute pressure to support those with bigger future potential, according to a survey conducted by McKinsey & Company.
You may also be interested in...
Pfizer Inc. and Shanghai-based Zhejiang Hisun Pharmaceuticals announced June 2 a memorandum of understanding to potentially establish a joint venture to develop, manufacture and sell branded generics in China and other markets
In China, A Province's Drastic Price Cut Model Is Being Modified To Fit A Nationwide System: A Look At The Anhui Model
SHANGHAI - Since China's healthcare reforms started in 2009, the central government has been encouraging local government to pilot different tender models for essential drugs to reduce public medical expenses. Anhui Province's tender system became a successful example by reducing essential drug prices an average 40-50% last year, and now the central government is implementing a single supplier procurement system, the so-called Anhui model, nationwide
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.